scholarly journals Disposable Reagentless Electrochemical Immunosensor Array Based on a Biopolymer/Sol-Gel Membrane for Simultaneous Measurement of Several Tumor Markers

2008 ◽  
Vol 54 (9) ◽  
pp. 1481-1488 ◽  
Author(s):  
Jie Wu ◽  
Feng Yan ◽  
Xiaoqing Zhang ◽  
Yuetian Yan ◽  
Jinhai Tang ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Point Of Care ◽  
Sol Gel ◽  
Simultaneous Detection ◽  
Carbohydrate Antigen ◽  
Electrochemical Immunosensor ◽  
Point Of Care Testing ◽  
Serum Samples ◽  
Sampling Volume ◽  
Analytical Time

Abstract Background: A reagentless sensor array for simultaneous multianalyte testing (SMAT) may enable accurate diagnosis and be applicable for point-of-care testing. We developed a disposable reagentless immunosensor array for simple immunoassay of panels of tumor markers. Methods: We carried out SMAT with a direct capture format, in which colloidal gold nanoparticles with bound horseradish peroxidase (HRP)-labeled antibodies were immobilized on screen-printed carbon electrodes with biopolymer/sol-gel to trap their corresponding antigens from sample solution. Upon formation of immunocomplex, the direct electrochemical signal of the HRP decreased owing to increasing spatial blocking, and the analytes could be simultaneously determined by monitoring the signal changes. Results: The proposed reagentless immunosensor array allowed simultaneous detection of carcinoma antigen 153, carcinoma antigen 125, carbohydrate antigen 199, and carcinoembryonic antigen in clinical serum samples in the ranges of 0.4–140 kU/L, 0.5–330 kU/L, 0.8–190 kU/L, and 0.1–44 μg/L, respectively, with detection limits of 0.2 kU/L, 0.5 kU/L, 0.3 kU/L, and 0.1 μg/L corresponding to the signals 3 SD above the mean of a zero standard. The interassay imprecision of the arrays was <9.5%, and they were stable for 35 days. The positivity detection rate of panels of tumor markers was >95.5% for 95 cases of cancer-positive sera. Conclusions: The immunosensor array provides a SMAT with short analytical time, small sampling volume, no need for substrate, and, no between-electrode cross-talk. This method not only proved the capability of the array in point-of-care testing, but also allowed simultaneous testing of several tumor markers.

scholarly journals Wave-shaped microfluidic chip assisted point-of-care testing for accurate and rapid diagnosis of infections

2021 ◽  
Author(s):  
Binfeng Yin ◽  
Xinhua Wan ◽  
Mingzhu Yang ◽  
Changcheng Qian ◽  
A S M Muhtasim Fuad Sohan
Keyword(s):  
Microfluidic Chip ◽  
Limit Of Detection ◽  
Point Of Care ◽  
Simultaneous Detection ◽  
Accurate Diagnosis ◽  
Point Of Care Testing ◽  
Promising Alternative ◽  
Reactive Protein ◽  
Linear Relationships ◽  
Multiple Biomarkers

Abstract Background: Simultaneous and timely detection of C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) provides effective information for the accurate diagnosis of infections. Early diagnosis and classification of infections increase the cure rate while decreasing complications, which is significant for severe infections, especially for war surgery. However, traditional methods rely on laborious operations and bulky devices. On the other hand, point-of-care (POC) methods suffer from limited robustness and accuracy. Therefore, it is of urgent demand to develop POC devices for rapid and accurate diagnosis of infections to fulfill on-site militarized requirements.Methods: We developed a wave-shaped microfluidic chip (WMC) assisted multiplexed detection platform (WMC-MDP). WMC-MDP reduces detection time and improves repeatability through premixing of the samples and reaction of the reagents. We further combined the detection platform with the streptavidin-biotin (SA-B) amplified system to enhance the sensitivity while using chemiluminescence (CL) intensity as signal readout. We realized simultaneous detection of CRP, PCT, and IL-6 on the detection platform and evaluated the sensitivity, linear range, selectivity, and repeatability. Finally, we finished detecting 15 samples from volunteers and compared the results with commercial ELISA kits.Results: Detection of CRP, PCT, and IL-6 exhibited good linear relationships between CL intensities and concentrations in the range of 1.25-40 μg/mL, 0.4-12.8 ng/mL, and 50-1600 pg/mL. The limit of detection (LOD) of CRP, PCT, and IL-6 were 0.54 μg/mL, 0.11 ng/mL, and 16.25 pg/mL, respectively. WMC-MDP is capable of good adequate selectivity and repeatability. The whole detection procedure takes only 22 minutes that meets the requirements of a POC device. Results of 15 samples from volunteers were consistent with the results detected by commercial ELISA kits.Conclusion: WMC-MDP allows simultaneous, rapid, and sensitive detection of CRP, PCT, and IL-6 with satisfactory selectivity and repeatability, requiring minimal manipulation. However, WMC-MDP takes advantage of being a microfluidic device showing the coefficients of variation less than 10% enabling WMC-MDP to be a type of POCT. Therefore, WMC-MDP provides a promising alternative to point-of-care testing (POCT) of multiple biomarkers. We believe the practical application of WMC-MDP in militarized fields will revolutionize infection diagnosis for soldiers.

scholarly journals Electrochemical Immunosensor for Simultaneous Detection of Dual Cardiac Markers Based on a Poly(Dimethylsiloxane)-Gold Nanoparticles Composite Microfluidic Chip: A Proof of Principle

2010 ◽  
Vol 56 (11) ◽  
pp. 1701-1707 ◽  
Author(s):  
Fang Zhou ◽  
Min Lu ◽  
Wei Wang ◽  
Zhi-Ping Bian ◽  
Jian-Rong Zhang ◽  
...  
Keyword(s):  
Quantum Dots ◽  
Troponin I ◽  
Clinical Laboratory ◽  
Anodic Stripping Voltammetry ◽  
Simultaneous Detection ◽  
Protein Detection ◽  
Electrochemical Immunosensor ◽  
Quantitative Methodology ◽  
Serum Samples ◽  
Proof Of Principle

BACKGROUND The emergence of microfluidic immunosensors has provided a promising tool for improving clinical diagnoses. We developed an electrochemical immunoassay for the simultaneous detection of cardiac troponin I (cTnI) and C-reactive protein (CRP), based on microfluidic chips. METHODS The quantitative methodology was based on ELISA in poly(dimethylsiloxane)-gold nanoparticle composite microreactors. CdTe and ZnSe quantum dots were bioconjugated with antibodies for sandwich immunoassay. After the CdTe and ZnSe quantum dots were dissolved, Cd2+ and Zn2+ were detected by square-wave anodic stripping voltammetry to enable the quantification of the 2 biomarkers. The 2 biomarkers were measured in 20 human serum samples by using the proposed method and commercially available methods. RESULTS This immunosensor allowed simultaneous detection of serum cTnI and CRP. The linear range of this assay was between 0.01 and 50 μg/L and 0.5 and 200 μg/L, with the detection limits of approximately 5 amol and approximately 307 amol in 30-μL samples corresponding to cTnI and CRP, respectively. Slopes close to 1 and the correlation coefficient over 0.99 were obtained for both analytes. CONCLUSIONS This strategy demonstrates a proof of principle for the successful integration of microfluidics with electrochemistry that can potentially provide an alternative to protein detection in the clinical laboratory.

scholarly journals Three-Dimensional Paper-Based Microfluidic Analysis Device for Simultaneous Detection of Multiple Biomarkers with a Smartphone

Biosensors ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. 187
Author(s):  
Seung Ho Baek ◽  
Chanyong Park ◽  
Jaehyung Jeon ◽  
Sungsu Park
Keyword(s):  
Point Of Care ◽  
Simultaneous Detection ◽  
Three Dimensional ◽  
Cost Effective ◽  
Smartphone Application ◽  
Accurate Diagnosis ◽  
Point Of Care Testing ◽  
Digital Light Processing ◽  
Multiple Biomarkers ◽  
Microfluidic Analysis

Paper-based microfluidic analysis devices (μPADs) have attracted attention as a cost-effective platform for point-of-care testing (POCT), food safety, and environmental monitoring. Recently, three-dimensional (3D)-μPADs have been developed to improve the performance of μPADs. For accurate diagnosis of diseases, however, 3D-μPADs need to be developed to simultaneously detect multiple biomarkers. Here, we report a 3D-μPADs platform for the detection of multiple biomarkers that can be analyzed and diagnosed with a smartphone. The 3D-μPADs were fabricated using a 3D digital light processing printer and consisted of a sample reservoir (300 µL) connected to 24 detection zones (of 4 mm in diameter) through eight microchannels (of 2 mm in width). With the smartphone application, eight different biomarkers related to various diseases were detectable in concentrations ranging from normal to abnormal conditions: glucose (0–20 mmol/L), cholesterol (0–10 mmol/L), albumin (0–7 g/dL), alkaline phosphatase (0–800 U/L), creatinine (0–500 µmol/L), aspartate aminotransferase (0–800 U/L), alanine aminotransferase (0–1000 U/L), and urea nitrogen (0–7.2 mmol/L). These results suggest that 3D-µPADs can be used as a POCT platform for simultaneous detection of multiple biomarkers.

Sensitive electrochemical immunosensor array for the simultaneous detection of multiple tumor markers

The Analyst ◽  
2012 ◽  
Vol 137 (2) ◽  
pp. 393-399 ◽  
Author(s):  
Honglan Qi ◽  
Chen Ling ◽  
Qingyun Ma ◽  
Qiang Gao ◽  
Chengxiao Zhang
Keyword(s):  
Tumor Markers ◽  
Simultaneous Detection ◽  
Electrochemical Immunosensor ◽  
Multiple Tumor

scholarly journals P216 Comparative Assessment C-reactive Protein Between a Point-of-Care Testing and Current Standard of Care (Immunonephelometric testing)

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S272-S273
Author(s):  
G Lorenzon ◽  
I Marsilio ◽  
D Maniero ◽  
A Rigo ◽  
B Barberio ◽  
...  
Keyword(s):  
Inflammatory Disease ◽  
Point Of Care ◽  
Standard Of Care ◽  
Turnaround Time ◽  
Blood Collection ◽  
Standard Laboratory ◽  
Point Of Care Testing ◽  
C Reactive Protein ◽  
Serum Samples ◽  
Reactive Protein

Abstract Background C-reactive protein (CRP) is widely used as a biomarker of inflammatory disease activity in hospitalized and non-hospitalized patients. In particular, CRP is commonly used in patients suspected to have an inflammatory bowel disease (IBD) or with a confirmed diagnosis of IBD diagnosis in order to drive the diagnostic approach, to monitor disease activity and to guide therapeutic adjustments. However, standard laboratory CRP testing (Immunonephelometric assays) present some drawbacks, including a turnaround time of 1–2 hours, and the need of specialized equipment, offices and laboratory personnel. Because of that, point-of care testing (POCT) was recently developed in order to provide results within 2 minutes from blood collection, enabling a rapid response to clinical condition. Aim To determine the degree of analytical correlation between a recently developed POCT (ProciseDx) using capillary whole blood and the comparative Immunonephelometric assay using serum samples. Methods From October to November 2020, consecutive patients hospitalized at Gastroenterology Unit, Padua University Hospital, aged > 18 years and with clinical evidence of active inflammatory disease or infection, who underwent to a standard of care CRP test (Dimension Vista – Siemens Healthineers) were included in the study (range 2.9–340 g/L). Within 1 hour from blood collection, in each patient, CRP quantitation from capillary whole blood collected by finger stick was performed using the ProciseDx CRP assay, with reportable range between 3.6–100 g/L. A Deming regression test was used to identify the correlation between the two methods. Results Eighty-three patients were enrolled (62.5% males with mean age ± SD: 60±18). The most common indications for hospitalisation were liver disease (34.9%), pancreatic disturbance (27.7%) and suspicious or recurrence of IBD (16.7%). ProciseDx POCT with finger prick samples required a turnaround time of 2±0.2 minutes, whereas serum samples analyzed in clinical laboratory with the reference method required a turnaround time of about 180±15 minutes (p<0.001). Overall, the correlation between the two tests was high (R squared of 0.899 (95% CI 0.916–0.968)). In particular, the correlation between the methods was even higher with CRP values between 0–100 g/L with R squared of 0.961 (95% CI 0.958–0.986). Conclusion The ProciseDx POCT allows a more rapid and comparable accuracy of CRP assessment in hospitalized patients as compared to the standard laboratory measurement. Moreover, the ProciseDx POCT does not require specialised personnel to be performed. The use of ProciseDx POCT may improve and accelerate the decision-making approach, further reducing the resources required for CRP assessment.

scholarly journals Three-Dimensional Paper-Based Microfluidic Analysis Device for Simultaneous Detection of Multiple Biomarkers With a Smartphone

2020 ◽  
Author(s):  
Seung Ho Baek ◽  
Chanyong Park ◽  
Jaehyung Jeon ◽  
Sungsu Park
Keyword(s):  
Point Of Care ◽  
Simultaneous Detection ◽  
Three Dimensional ◽  
Cost Effective ◽  
Smartphone Application ◽  
Accurate Diagnosis ◽  
Point Of Care Testing ◽  
Digital Light Processing ◽  
Multiple Biomarkers ◽  
Microfluidic Analysis

Paper-based microfluidic analysis devices (μPADs) have attracted attention as a cost-effective platform for point-of-care testing (POCT), food safety, and environmental monitoring. Recently, three-dimensional (3D)-μPADs have been developed to improve the performance of μPADs. For accurate diagnosis of diseases, however, 3D-μPADs need to be developed to simultaneously detect multiple biomarkers. Here, we report a 3D-μPADs platform for the detection of multiple biomarkers that can be analyzed and diagnosed with a smartphone. The 3D-μPADs were fabricated using a 3D digital light processing printer and consisted of a sample reservoir (300 µL) connected to 24 detection zones (of 4 mm in diameter) through 8 microchannels (of 2 mm in width). With the smartphone application, eight different biomarkers related to various diseases were detectable in concentrations ranging from normal to abnormal conditions: glucose (0–20 mmol/L), cholesterol (0–10 mmol/L), albumin (0–7 g/dL), alkaline phosphatase (0–800 U/L), creatinine (0–500 µmol/L), aspartate aminotransferase (0–800 U/L), alanine aminotransferase (0–1000 U/L), and urea nitrogen (0–7.2 mmol/L). These results suggest that 3D-µPADs can be used as a POCT platform for simultaneous detection of multiple biomarkers.

scholarly journals Rapid Detection of SARS-CoV-2 Antigen from Serum in a Hospitalized Population

2020 ◽  
Author(s):  
K McAulay ◽  
EJ Kaleta ◽  
TE Grys
Keyword(s):  
Symptom Onset ◽  
Rapid Detection ◽  
Medical Technology ◽  
Point Of Care ◽  
Antigen Test ◽  
Point Of Care Testing ◽  
Serum Samples ◽  
Time Points ◽  
Molecular Assays ◽  
Proof Of Principle

AbstractSARS-CoV-2 viremia has been demonstrated in some patients using molecular assays. Here we demonstrate detection of SARS-CoV-2 antigen in a cohort of hospitalized patients using a rapid diagnostic test from Anhui Deepblue Medical Technology Co., Ltd. We detected antigen in serum from 11 of 13 patients at time points ranging from three to eighteen days from symptom onset and observed that the disappearance of an antigen signal was associated with seroconversion. These results demonstrate proof of principle use of a rapid antigen test with serum samples in a format compatible with point of care testing.

Sign in / Sign up

Export Citation Format

Share Document